The Trump administration has bought up the world's supply of COVID-19 drug remdesivir


Health and Human Services Secretary Alex Azar announced Monday an "amazing deal" reached by the Trump administration to purchase nearly all of Gilead's supply of the antiviral drug remdesivir through September. Other countries, which now won't have access to one of two proven treatments for COVID-19 for three months, did not see the deal as so amazing, at least not in the sense Azar meant.
The U.S. "got access to most of the drug supply, so there's nothing for Europe," Dr. Andrew Hill, a research fellow at Liverpool University, told The Guardian. "Imagine this was a vaccine," he added. "That would be a firestorm. But perhaps this is a taste of things to come."
Azar said the U.S. has reserved 100 percent of Gilead's remdesivir production in July and 90 percent in August and September, for a total of about 500,000 doses. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it," Azar said. Each treatment course requires an average of 6.25 vials of remdesivir at a cost of $3,200, HHS said. In other developed countries, Gilead announced, a course of treatment will cost nearly $1,000 less, or $2,340.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The U.S. has the world's worst confirmed COVID-19 outbreak by far — 2.6 million of the world's 10.5 million confirmed cases, 127,000 of 512,000 confirmed deaths — and the disease is not under control. But "the U.S. has taken an 'America first' attitude throughout the global pandemic," The Guardian says, trying to negotiate exclusive rights to a German vaccine and briefly securing first dibs on another vaccine from French pharmaceutical firm Sanofi — before Germany and France, respectively, stepped in.
Remdesivir, developed to fight Ebola (unsuccessfully), has been shown to reduce hospital stays for COVID-19 patients with severe cases. The only other treatment found to be effective is the steroid dexamethasone, which reduced the number of deaths by up to a third in a British study. "There has been no attempt to buy up the world's stocks of dexamethasone because there is no need," The Guardian notes: "The drug is 60 years old, cheap, and easily available everywhere."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures
-
Starbucks baristas strike over dress code
speed read The new uniform 'puts the burden on baristas' to buy new clothes, said a Starbucks Workers United union delegate
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement
-
Trump calls Amazon's Bezos over tariff display
Speed Read The president was not happy with reports that Amazon would list the added cost from tariffs alongside product prices
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores